An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent details new cannabinoid CB2 receptor modulators reported to be useful for the treatment of neuropathic pain, asthma, osteoporosis, inflammation, psychosis, cancer, malaria, gastrointestinal disorders, allergy and immunological disorders, among others.